Placenta-Derived Nasal Spray Shields Mouse Brains From Alzheimer's Damage
Finn's Take· TL;DR- Placenta-derived extracellular vesicles in nasal spray form reduced neuroinflammation and improved memory in Alzheimer's-model mice over six months.
- The spray successfully delivered particles to the hippocampus, bypassing the blood-brain barrier and demonstrating protective effects on brain function and neuronal plasticity.
- Results are preclinical and require human validation before becoming an available therapy, but researchers highlight promising potential for treating neurodegenerative diseases.
An Unlikely Source for a Brain-Protecting Treatment
Most Alzheimer's research has focused on the sticky proteins amyloid-beta and tau, which are hallmark features of the disease — but they're not the only contributors. Another key factor in cognitive decline is the chronic activation of specific brain cells, namely microglia and astrocytes, which can damage neurons through a process called neuroinflammation. Now, a team of scientists thinks they may have found a way to fight back against that inflammation using a source that few would have expected: the human placenta.
Published in the journal *Translational Neurodegeneration*, the study describes how a team led by scientists from the Catholic University of the Sacred Heart in Italy treated mice with a nasal formulation containing tiny particles called extracellular vesicles, derived from cells found in the human placenta. The concept may sound unusual, but it's rooted in a growing field of regenerative medicine that looks to the body's own biological machinery for therapeutic tools.
How the Spray Works — and What It Did
The scientists used a specific type of vesicle known as human amniotic mesenchymal stromal cell-derived vesicles, or hAMSC-EVs, sourced from the placental amniotic membrane. The nasal spray formulation was then administered to transgenic mice that had been genetically engineered to develop features of Alzheimer's disease.
The mice received doses of the experimental spray twice a week for six months, beginning at three months of age — before they had manifested any Alzheimer's-like symptoms — and continuing through nine months of age. Tests using fluorescent dyes confirmed that the hAMSC-EVs successfully reached all regions of the hippocampus, the brain's primary memory center, and were co-localized with both neurons and microglia.
Behavioral tests showed that mice treated with the hAMSC-EVs formulation exhibited improved cognitive performance compared to control animals in tests measuring object recognition and spatial memory. The treatment also demonstrated beneficial effects on neuronal plasticity and memory processes more broadly. In short, the spray didn't just slow decline — it appeared to actively protect brain function.
Why the Placenta? The Biology Behind the Idea
The placenta is one of the most immunologically sophisticated organs in the human body. It must simultaneously protect a developing fetus while tolerating the mother's immune system — a feat that requires extraordinary anti-inflammatory capabilities. Researchers believe those same properties can be harnessed to calm the runaway inflammation that ravages the Alzheimer's brain.
The study was conducted by researchers at the Università Cattolica, Fondazione Policlinico Universitario A. Gemelli IRCCS, and the E. Menni Research Center of Fondazione Poliambulanza. The nasal delivery route is also significant — it offers a direct pathway to the brain, bypassing the blood-brain barrier that makes so many potential neurological treatments difficult to administer effectively.
Promising, But Still Early Days
Scientists are careful to frame these findings as a starting point, not a finish line. The lead researcher concluded that "these are preclinical results that require further validation in humans and do not yet represent an available therapy for Alzheimer's disease," but added that they "point to a very promising direction."
The researchers believe the study raises a compelling question: whether some of the mechanisms through which the placenta naturally regulates inflammation and protects tissues could offer new tools for treating neurodegenerative diseases — and whether extracellular vesicles represent a new frontier for neurological treatment altogether. With over 55 million people living with dementia worldwide and no cure in sight, even a promising early-stage finding like this one carries real weight. If the results translate to human trials, a simple nasal spray could one day become part of the arsenal against one of medicine's most stubborn and devastating diseases.